Nama's AI scorecard currently rates COMPASS Pathways Sell (1.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does CMPS report earnings?

COMPASS Pathways's next scheduled report is on Mar 23, 2027. Analysts expect EPS of -$0.39.

What is the CMPS price target?

The median analyst price target from 16 analysts is $21.00, with a range of $13.00 – $65.00.

Is CMPS Shariah compliant?

Nama's AAOIFI-style screen reads COMPASS Pathways as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

COMPASS Pathways (CMPS)

Healthcare · Medical Care Facilities · NASDAQ

COMPASS Pathways (CMPS) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $1.22B and a free-cash-flow yield of -19.5%. Nama's AI scorecard rates it Sell, 1.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 1.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +109.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-82.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.22B
Trailing P/E	—
Price / book	13.9
Price / sales	—
FCF yield	-19.5%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

CMPS earnings

Next report: Mar 23, 2027 (Q4 2026, EPS estimate -$0.39). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$0.34	-$0.33	-3.0%	$0
Q2 2026	Aug 5, 2026	-$0.36	-$0.33	-9.1%	$0
Q1 2026	May 13, 2026	-$0.30	-$0.31	+3.2%	$0
Q4 2025	Mar 24, 2026	-$0.61	-$0.39	-56.4%	$0

CMPS analyst price target

Median target $21.00 from 16 analysts, ranging $13.00 – $65.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live CMPS data on Nama Insights →

CMPS FAQ

Is CMPS a buy?: Nama's AI scorecard currently rates COMPASS Pathways Sell (1.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CMPS report earnings?: COMPASS Pathways's next scheduled report is on Mar 23, 2027. Analysts expect EPS of -$0.39.
What is the CMPS price target?: The median analyst price target from 16 analysts is $21.00, with a range of $13.00 – $65.00.
Is CMPS Shariah compliant?: Nama's AAOIFI-style screen reads COMPASS Pathways as Not Shariah Compliant. At least one of the three ratios or the industry test failed.